ce41f5d1-6e6d-4fc8-b8ed-a9479bcc8add
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.390
- TGF_BETA_SIGNALING+0.370
- WNT_BETA_CATENIN_SIGNALING+0.370
- E2F_TARGETS+0.310
- G2M_CHECKPOINT+0.310
- MYC_TARGETS_V1+0.310
- BILE_ACID_METABOLISM+0.110
- APICAL_SURFACE+0.100
- COAGULATION+0.100
- ANDROGEN_RESPONSE+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.540
- INTERFERON_GAMMA_RESPONSE-0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.460
- TNFA_SIGNALING_VIA_NFKB-0.390
- CHOLESTEROL_HOMEOSTASIS-0.380
- OXIDATIVE_PHOSPHORYLATION-0.280
- IL6_JAK_STAT3_SIGNALING-0.260
- UNFOLDED_PROTEIN_RESPONSE-0.250
- ALLOGRAFT_REJECTION-0.220
- GLYCOLYSIS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 955985ca-7d97-4911-927a-3803e669a805 | — | — | 0.789 |
| 2 | SRR10899974 | — | — | 0.760 |
| 3 | SRR8392888 | — | cohortMD1 | 0.753 |
| 4 | b0be4742-ccb7-48e2-b756-0c384321114e | — | — | 0.753 |
| 5 | 0918cbd5-edd0-41c8-8b67-677f35ad4611 | — | — | 0.749 |
| 6 | 20100144.Her2HRpos | — | D | 0.748 |
| 7 | TCGA-CR-7370-01A-11R-2132-07 | — | — | 0.744 |
| 8 | TCGA-56-8083-01A-11R-2247-07 | — | cohortMD1 | 0.743 |
| 9 | ERR2208889 | — | — | 0.734 |
| 10 | s0122214 | — | — | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.390 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.370 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.020 | Inavolisib | — uncovered |